Mangiferin, an anti-HIV-1 agent targeting protease and effective against resistant strains. 2011

Rui-Rui Wang, and Yue-Dong Gao, and Chun-Hui Ma, and Xing-Jie Zhang, and Cheng-Gang Huang, and Jing-Fei Huang, and Yong-Tang Zheng
Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences & Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China.

The anti-HIV-1 activity of mangiferin was evaluated. Mangiferin can inhibit HIV-1(Ⅲ)(B) induced syncytium formation at non-cytotoxic concentrations, with a 50% effective concentration (EC₅₀) at 16.90 μM and a therapeutic index (TI) above 140. Mangiferin also showed good activities in other laboratory-derived strains, clinically isolated strains and resistant HIV-1 strains. Mechanism studies revealed that mangiferin might inhibit the HIV-1 protease, but is still effective against HIV peptidic protease inhibitor resistant strains. A combination of docking and pharmacophore methods clarified possible binding modes of mangiferin in the HIV-1 protease. The pharmacophore model of mangiferin consists of two hydrogen bond donors and two hydrogen bond acceptors. Compared to pharmacophore features found in commercially available drugs, three pharmacophoric elements matched well and one novel pharmacophore element was observed. Moreover, molecular docking analysis demonstrated that the pharmacophoric elements play important roles in binding HIV-1 protease. Mangiferin is a novel nonpeptidic protease inhibitor with an original structure that represents an effective drug development strategy for combating drug resistance.

UI MeSH Term Description Entries
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D016333 HIV Protease Enzyme of the human immunodeficiency virus that is required for post-translational cleavage of gag and gag-pol precursor polyproteins into functional products needed for viral assembly. HIV protease is an aspartic protease encoded by the amino terminus of the pol gene. HIV Proteinase,HTLV-III Protease,p16 pol gene product, HIV,p16 protease, HIV,HIV p16 protease,HTLV III Protease,Protease, HIV,Protease, HTLV-III
D044004 Xanthones A group of XANTHENES that contain a 9-keto OXYGEN. Xanthone Derivatives,Derivatives, Xanthone
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

Rui-Rui Wang, and Yue-Dong Gao, and Chun-Hui Ma, and Xing-Jie Zhang, and Cheng-Gang Huang, and Jing-Fei Huang, and Yong-Tang Zheng
December 2018, Molecular medicine reports,
Rui-Rui Wang, and Yue-Dong Gao, and Chun-Hui Ma, and Xing-Jie Zhang, and Cheng-Gang Huang, and Jing-Fei Huang, and Yong-Tang Zheng
July 2017, The Journal of infection,
Rui-Rui Wang, and Yue-Dong Gao, and Chun-Hui Ma, and Xing-Jie Zhang, and Cheng-Gang Huang, and Jing-Fei Huang, and Yong-Tang Zheng
December 2002, Journal of molecular biology,
Rui-Rui Wang, and Yue-Dong Gao, and Chun-Hui Ma, and Xing-Jie Zhang, and Cheng-Gang Huang, and Jing-Fei Huang, and Yong-Tang Zheng
November 2003, Bioorganic & medicinal chemistry letters,
Rui-Rui Wang, and Yue-Dong Gao, and Chun-Hui Ma, and Xing-Jie Zhang, and Cheng-Gang Huang, and Jing-Fei Huang, and Yong-Tang Zheng
October 2008, Proceedings of the National Academy of Sciences of the United States of America,
Rui-Rui Wang, and Yue-Dong Gao, and Chun-Hui Ma, and Xing-Jie Zhang, and Cheng-Gang Huang, and Jing-Fei Huang, and Yong-Tang Zheng
February 2019, Microbial pathogenesis,
Rui-Rui Wang, and Yue-Dong Gao, and Chun-Hui Ma, and Xing-Jie Zhang, and Cheng-Gang Huang, and Jing-Fei Huang, and Yong-Tang Zheng
April 2003, Journal of medicinal chemistry,
Rui-Rui Wang, and Yue-Dong Gao, and Chun-Hui Ma, and Xing-Jie Zhang, and Cheng-Gang Huang, and Jing-Fei Huang, and Yong-Tang Zheng
February 2004, Bioorganic & medicinal chemistry letters,
Rui-Rui Wang, and Yue-Dong Gao, and Chun-Hui Ma, and Xing-Jie Zhang, and Cheng-Gang Huang, and Jing-Fei Huang, and Yong-Tang Zheng
January 2020, Frontiers in microbiology,
Rui-Rui Wang, and Yue-Dong Gao, and Chun-Hui Ma, and Xing-Jie Zhang, and Cheng-Gang Huang, and Jing-Fei Huang, and Yong-Tang Zheng
September 2004, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!